Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
Bathla Group Hires Administrators as Australia Housing Slump Deepens 
SpaceX Hires Natural Gas Trader to Meet Growing Energy Needs 
Nvidia Options Price in $280 Billion Earnings Swing 
J.P. Morgan Upgrades Diploma, Lifts Price Target to 8,250p 
Shein Launches $1.77 Billion Hong Kong IPO After Years of Listing Delays 
KPMG Australia Cuts 5% of Workforce Amid Scandal 
Samsung Shares Tumble 8% as $79 Billion Return Plan Disappoints 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
Tesla Raises Cybertruck Prices by $5,000 in US 
China EV Stocks Slide as Door Handle Recall Hits 4.3 Million Vehicles 
Nvidia Eyes Perplexity Investment at $30 Billion Valuation 
Exxon, LyondellBasell Eye Shell’s $8 Billion U.S. Chemicals Assets 
SK Hynix Shares Fall as Workers Reject Wage Deal 
Xiaomi Unveils Xring O3 Chip for Flagship Foldable Phone 
Add as a preferred source on Google
CANTON, Mass., May 02, 2018 -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at the Deutsche Bank 43rd Annual Health Care Conference on Tuesday, May 8, 2018 at 12:50 p.m. ET at the Intercontinental Hotel Boston.
About Collegium Pharmaceutical, Inc.
Collegium is a specialty pharmaceutical company focused on becoming the leader in responsible pain management by developing and commercializing innovative, differentiated products for patients suffering from pain.
About Xtampza ER
Xtampza® ER is Collegium’s first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Contact:
Alex Dasalla
[email protected]
